COMMUNIQUÉS West-GlobeNewswire

-
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
10/02/2025 -
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
10/02/2025 -
KFSHRC Detects 276 Fetal Genetic Disorders Through Prenatal Care Saving SAR 360 Million Annually
10/02/2025 -
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
10/02/2025 -
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
10/02/2025 -
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
10/02/2025 -
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
10/02/2025 -
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
10/02/2025 -
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
10/02/2025 -
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
10/02/2025 -
Mustang Bio Announces Closing of $8 Million Public Offering
10/02/2025 -
Qu Biologics’ Immunomodulator Clears Senescence
10/02/2025 -
Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
10/02/2025 -
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
10/02/2025 -
Saudi Arabia’s KFSHRC Continues to Rise as a Globally Renowned Medical Centre
09/02/2025 -
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
08/02/2025 -
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
08/02/2025 -
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
08/02/2025 -
REPEAT - MEDIA ADVISORY: Public healthcare advocates to protest at Minister of Health Sylvia Jones’ office
08/02/2025
Pages